Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

Gianni Bisogno(University of Padua), Gian Luca De Salvo(Istituto Oncologico Veneto), Christophe Bergeron(Institut d’Hématologie et d’Oncologie Pédiatrique), Soledad Gallego Melcón(Vall d'Hebron Hospital Universitari), Johannes H. M. Merks(Amsterdam UMC Location University of Amsterdam), Anna Kelsey(Royal Manchester Children's Hospital), Hélène Martelli(Assistance Publique – Hôpitaux de Paris), Véronique Minard‐Colin(Institut Gustave Roussy), Daniel Orbach(Université Paris Sciences et Lettres), Heidi Glosli(Oslo University Hospital), Julia Chisholm(Royal Marsden NHS Foundation Trust), Michela Casanova(Fondazione IRCCS Istituto Nazionale dei Tumori), Ilaria Zanetti(University of Padua), Christine Devalck(Université Libre de Bruxelles), Myriam Ben-Arush(Rambam Health Care Campus), Peter Múdrý(University Hospital Brno), Sima Ferman(Instituto Nacional de Câncer - INCA), Meriel Jenney(Noah's Ark Children's Hospital for Wales), Andrea Ferrari(Fondazione IRCCS Istituto Nazionale dei Tumori)
The Lancet Oncology
September 24, 2019
Cited by 238Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis